Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
epcoritamab + etoposide + cyclophosphamide + vincristine + doxorubicin + prednisone + rituximab
- Development stage
- Phase 2
- Lead developer
- Genmab
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral, Subcutaneous
01
Overview
This investigational chemoimmunotherapy regimen combines the CD3xCD20 bispecific T-cell engager epcoritamab with the dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) chemotherapy backbone. It is being evaluated in clinical trials, such as the Phase II BEDROCK study (NCT07662928) and an investigator-initiated Phase II trial (NCT07097363), for the treatment of aggressive B-cell non-Hodgkin lymphomas, including high-risk Burkitt lymphoma and high-grade B-cell lymphoma. Epcoritamab redirects T-cell-mediated cytotoxicity against CD20-expressing malignant B cells, while the EPOCH-R regimen provides intensive, multi-targeted cytotoxic chemotherapy and anti-CD20 monoclonal antibody therapy to maximize tumor cytoreduction.
- Other names
- epcoritamab + DA-EPOCH-Repcoritamab + EPOCH-Repcoritamab + dose-adjusted EPOCH-Repcoritamab plus DA-EPOCH-Repcoritamab plus EPOCH-R
02
Targets
CD20 (B-lymphocyte antigen CD20)DNATOP2A (DNA topoisomerase II)TOP2B (DNA topoisomerase II beta)GR (Glucocorticoid receptor)CD3 (T-cell surface glycoprotein CD3)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on epcoritamab + etoposide + cyclophosphamide + vincristine + doxorubicin + prednisone + rituximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on epcoritamab + etoposide + cyclophosphamide + vincristine + doxorubicin + prednisone + rituximab.